BioFactura, Inc. publishes Phase 1 data on its Ustekinumab biosimilar

BioFactura, Inc. announced the publication of the phase 1 study for BFI-751, a biosimilar candidate to Stelara (ustekinumab) in the peer reviewed journal, Clinical Pharmacology in Drug Development FREDERICK, Md., Sept. 11, 2023 /PRNewswire-PRWeb/ -- BioFactura, Inc. announced the...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news